Interview: AIRSCREAM on Balancing Compliance and Market Demand Amid the Disposable Vape Crackdown

Jul.04.2025
Interview: AIRSCREAM on Balancing Compliance and Market Demand Amid the Disposable Vape Crackdown
During the Dubai World Vape Show, AIRSCREAM executive Andrew spoke with 2Firsts about the brand’s strategies on compliance, large-capacity products, and nicotine alternatives. He underscored the company’s stance against disposable vapes and its commitment to long-termism and youth protection.

【By 2Firsts】As growth in disposable vapes plateaus and regulations tighten worldwide, global e-cigarette companies face a pressing challenge: how to achieve product iteration and brand expansion without crossing regulatory lines. At the Dubai World Vape Show in June, 2Firsts sat down with Andrew Koh, AIRSCREAM’s Global Head of Market, Brand, and Communications, to discuss the UK-based brand’s strategic responses to regulatory pressures. During the event, AIRSCREAM unveiled its large-capacity refillable device, the AirsPops ORKA, while reiterating its commitment to nicotine alternatives and outlining its compliance-driven strategy.

 

 

No Disposable Vapes: Launching a 20ml Refillable Device
 

As disposables become a frequent target for regulators, AIRSCREAM showcased the AirsPops ORKA—a 20ml large-capacity refillable device—at the expo. Designed with the brand’s signature minimalist style, the ORKA avoids flashy colors and screens. According to Andrew, the device is aimed primarily at markets like the Middle East, where large-capacity devices remain permissible.

 

专访 AIRSCREAM:在一次性产品受压时代,如何在合规与市场之间坚持长期主义?
After the interview, Andrew showcases the AirsPops ORKA at the booth | Photo: 2Firsts

 

“We do not encourage disposable products. Instead, we want users to adopt refillable devices for repeated use, reducing waste and potentially slowing the pace of regulatory tightening,” he emphasized.

 

This stance is not new. As early as the 2023 Dubai expo, AIRSCREAM had voiced clear concerns about the environmental impact of disposable e-cigarettes in an interview with 2Firsts.

 

 

Oral Nicotine Sees Rapid Growth: Focus on M13 Series

 

At the same time, AIRSCREAM showcased its oral nicotine brand M13, which includes two product lines: nicotine pouches and nicotine strips. The Flavour Boozt series, in particular, enhances aroma release by incorporating flavor capsules into the pouches, offering a differentiated user experience.

 

专访 AIRSCREAM:在一次性产品受压时代,如何在合规与市场之间坚持长期主义?
AIRSCREAM unveils nicotine strips at the Dubai expo | Photo: 2Firsts

 

AIRSCREAM established a nicotine pouch R&D lab in the Czech Republic as early as 2023, focusing on formula innovation and compliance development for this product category.

 

Andrew noted that while e-cigarettes remain the company’s main revenue driver, its nicotine alternatives business is growing rapidly, with R&D investment increasing year by year.

 

 

Adapting to Global Regulatory Differences with Flexible Market Strategies

 

AIRSCREAM now operates in over 60 countries worldwide, employing a variety of market entry models tailored to local conditions.

 

In New Zealand, the brand focuses on product and brand development, while compliance and sales are managed by local distributors. This collaborative model helps avoid direct regulatory exposure and ensures consistent brand messaging.

 

专访 AIRSCREAM:在一次性产品受压时代,如何在合规与市场之间坚持长期主义?
AIRSCREAM unveils nicotine pouches at the Dubai expo | Photo: 2Firsts

 

In Australia, AIRSCREAM has chosen to enter the market via the “pharmaceutical pathway,” where products require a doctor’s prescription and are sold through pharmacies, rather than being managed as conventional vaping products. “This is not a vape market; it’s a pharmaceutical protocol,” Andrew emphasized.

 

He added that Africa, with its stable regulations and clear market structure, is set to become a key focus for the brand’s next phase of expansion.

 

 

Youth Protection as a Bottom Line: No Candy-Flavored Vapes

 

When discussing nicotine alternatives, Andrew repeatedly highlighted the importance of child-resistant packaging and youth protection. “Many people ask why we make our packaging so hard to open. We respond with one question: If your product were misused by a child, could you still sleep at night?” he said.

 

专访 AIRSCREAM:在一次性产品受压时代,如何在合规与市场之间坚持长期主义?
Andrew demonstrates the M13 nicotine pouch packaging’s youth-protection design to 2Firsts staff | Photo: 2Firsts

 

In his view, protecting minors is not only a matter of regulatory compliance but also a crucial component of AIRSCREAM’s commitment to a “long-termism” strategy. “We are fully capable of making our products as attractive as candy, but we choose not to. That is our bottom line.”

 

Andrew explained that this philosophy of “going the extra mile” permeates every detail of product design—from the packaging of nicotine products to the overall structure of the packaging. AIRSCREAM repeatedly emphasizes a clear boundary of “adults only,” rather than lowering usage barriers to capture a larger market.

 

This approach is also reflected in their product line and the style presented on their official website: minimalist design, restrained use of color, and a rejection of any flashy or entertainment-oriented visual elements.

 

 

“Not Building Products Just for Today”

 

Before the interview concluded, Andrew left a telling summary:

 

“If we only build products for today, there will be no story to tell tomorrow.”

 

Against the backdrop of the decline of disposable product logic and the comprehensive tightening of regulations, AIRSCREAM is striving to demonstrate that the e-cigarette industry can also advance steadily and sustainably under a long-termist vision.

 


Click on the image below to access the featured article.

 

Nicotine Pouches Gain Ground in U.S. Convenience Stores as Vape Unit Sales Fall 14%
Nicotine Pouches Gain Ground in U.S. Convenience Stores as Vape Unit Sales Fall 14%
According to convenience retail publication CStore Decisions, U.S. convenience store tobacco categories are undergoing a structural shift. Based on Circana OmniMarket Total U.S. Convenience data for the 52 weeks ending June 14, 2026, cigarettes remained the largest category with $50.8 billion in sales, but unit sales declined 5.3%. Electronic smoking devices and vaping products also declined, while modern oral nicotine products continued to grow, with nicotine pouch sales rising 29% in dollars and 17% in units. Retailers said changing consumer preferences are reshaping tobacco product assortments at convenience stores.
Regulations
Aug.07
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives